Drug Trial Radar · NCT06492005
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jul 26, 2024
Primary completion
Jul 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
Conditions
- Triple-Negative Breast Cancer
Interventions
9MW2821Drug
Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
PD-1 inhibitiorDrug
Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.